<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054064</url>
  </required_header>
  <id_info>
    <org_study_id>PHIND_CVA01</org_study_id>
    <nct_id>NCT03054064</nct_id>
  </id_info>
  <brief_title>Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA</brief_title>
  <official_title>Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parker Hannifin Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shepherd Center, Atlanta GA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheltering Arms Physical Rehabilitation Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shirley Ryan AbilityLab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kessler Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Charles Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TIRR Memorial Hermann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rusk Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parker Hannifin Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the Indego
      exoskeleton as a gait training tool for individuals with hemiplegia due to Cerebrovascular
      Accident (CVA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2017</start_date>
  <completion_date type="Actual">January 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Individuals With Hemiplegia Due to CVA Using the Indego Measured Through Reported Subject Adverse Events and Serious Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Safety of individuals with hemiplegia due to CVA using the Indego measured through reported Subject Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spasticity of Bilateral Upper Extremities (UE) and Lower Extremities (LE) Measured With Modified Ashworth Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Spasticity measured with Modified Ashworth Scale (MAS)
0 - No increase in muscle tone
1 - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
1+ - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM) 2 - More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved 3 - Considerable increase in muscle tone, passive movement difficult 4 - Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity Measured by Functional Ambulation Category</measure>
    <time_frame>2 weeks</time_frame>
    <description>Activity measured by Functional Ambulation Category (FAC)
unable to ambulate/ambulates only in parallel bars/requires supervision or physical assistance from &gt; 1 person
requires manual contact of one person during ambulation on level surfaces/manual contact is continuous and necessary to support body weight and/or to maintain balance or assist coordination
requires manual contact of one person during ambulation on level surfaces/manual contact is continuous or intermittent light touch to assist balance or coordination
ambulation occurs on level surfaces without manual contact of another person/requires stand-by guarding of one person because of poor judgment, questionable cardiac status, or the need for verbal cuing to complete the task
ambulation is independent on level surfaces/requires supervision/physical assistance to negotiate stairs, inclines, or unlevel surfaces
ambulation is independent on unlevel and level surfaces, stairs and inclines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Speed (Without Indego) Measured With 10 Meter Walk Test</measure>
    <time_frame>2 weeks</time_frame>
    <description>10 Meter Walk Test (MWT) without Indego to measure gait speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Measured With Face, Legs, Activity, Cry, Consolability Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pain measured with Face, Legs, Activity, Cry, Consolability (FLACC) Scale Face 0: no particular expression or smile
occasional grimace or frown, withdrawn, disinterested
frequent to constant frown, clenched jaw, quivering chin
Legs 0: normal position or relaxed
uneasy, restless, tense
kicking, or legs drawn up
Activity 0: lying quietly, normal position, moves easily
squirming, shifting back and forth, tense
arched, rigid, or jerking
Cry 0: no cry (awake or asleep)
moans or whimpers, occasional complaint
crying steadily, screams or sobs, frequent complaints
Consolability 0: content, relaxed
reassured by occasional touching, hugging, or being talked to, distractable
difficult to console or comfort
Minimum score: 0 Maximum Score: 10</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cerebrovascular Accident (CVA)</condition>
  <condition>Stroke</condition>
  <condition>Hemiplegia</condition>
  <arm_group>
    <arm_group_label>All Enrolled Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will receive gait training with the Indego.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indego Exoskeleton</intervention_name>
    <description>Six study sessions including five Indego training sessions over two weeks.</description>
    <arm_group_label>All Enrolled Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Height 5'1&quot; to 6'3&quot; (acceptable height may vary by a few inches depending on femur
             length)

          -  Weight 250 pounds or less

          -  History of one sided ischemic or hemorrhagic stroke with resultant hemiparesis

          -  Manual Muscle Test (MMT) 4/5 in at least upper extremity

          -  No restrictions on time since stroke (acuity), but all subjects need to be cleared by
             MD for locomotor training

          -  No other brain abnormalities or neurological diseases/disorders

          -  Has not been diagnosed with more than one stroke

          -  Passive range of motion (PROM) at shoulders, trunk, hips, knees and ankles within
             functional limits for safe gait

          -  Skin intact where interfaces with Indego device

          -  Modified Ashworth Scale (MAS) for spasticity 3 or less in the lower extremities

          -  Absence of complicating physical or mental conditions as determined by MD that would
             preclude the individual from safely participating in gait training

          -  Must be able to follow directions and communicate basic needs, demonstrated by a Mini-
             Mental State Exam (MMSE) score of 18 or greater

        Exclusion Criteria:

          -  Failure to meet all inclusion criteria

          -  Pregnancy

          -  Colostomy bag

          -  Uncontrolled/untreated hyper- or hypotension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Health System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago (Shirley Ryan AbilityLab)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kessler Foundation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Hospital</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TIRR Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheltering Arms Physical Rehabilitation Centers</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <results_first_submitted>April 17, 2019</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemiplegia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03054064/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Enrolled Subjects</title>
          <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lower Extremity Deep Vein Thrombosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bladder Issue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>High Blood Pressure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in Status</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled Subjects</title>
          <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic, Latino or other Spanish origin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acuity of Cerebrovascular Accident (CVA)</title>
          <description>Acute: less than 2 months since CVA, Sub-acute: 2-6 months since CVA, or Chronic: more than 6 months since CVA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Acute</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subacute</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of Cerebrovascular Accident (CVA)</title>
          <description>Mild: Fugl-Meyer Motor Assessment score greater than 79, Moderate: Fugl-Meyer Motor Assessment score 56-79, Severe: Fugl-Meyer Motor Assessment score 36-55, or Very Severe: Fugl-Meyer Motor Assessment score 0-35</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Individuals With Hemiplegia Due to CVA Using the Indego Measured Through Reported Subject Adverse Events and Serious Adverse Events</title>
        <description>Safety of individuals with hemiplegia due to CVA using the Indego measured through reported Subject Adverse Events and Serious Adverse Events</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Enrolled Subjects</title>
            <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Individuals With Hemiplegia Due to CVA Using the Indego Measured Through Reported Subject Adverse Events and Serious Adverse Events</title>
          <description>Safety of individuals with hemiplegia due to CVA using the Indego measured through reported Subject Adverse Events and Serious Adverse Events</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trial-related Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial-related Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spasticity of Bilateral Upper Extremities (UE) and Lower Extremities (LE) Measured With Modified Ashworth Scale</title>
        <description>Spasticity measured with Modified Ashworth Scale (MAS)
0 - No increase in muscle tone
1 - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
1+ - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM) 2 - More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved 3 - Considerable increase in muscle tone, passive movement difficult 4 - Affected part(s) rigid in flexion or extension</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Enrolled Subjects</title>
            <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Spasticity of Bilateral Upper Extremities (UE) and Lower Extremities (LE) Measured With Modified Ashworth Scale</title>
          <description>Spasticity measured with Modified Ashworth Scale (MAS)
0 - No increase in muscle tone
1 - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
1+ - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM) 2 - More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved 3 - Considerable increase in muscle tone, passive movement difficult 4 - Affected part(s) rigid in flexion or extension</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average MAS Right UE Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Left UE Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Right LE Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Left LE Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Right UE Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Left UE Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Right LE Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average MAS Left LE Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activity Measured by Functional Ambulation Category</title>
        <description>Activity measured by Functional Ambulation Category (FAC)
unable to ambulate/ambulates only in parallel bars/requires supervision or physical assistance from &gt; 1 person
requires manual contact of one person during ambulation on level surfaces/manual contact is continuous and necessary to support body weight and/or to maintain balance or assist coordination
requires manual contact of one person during ambulation on level surfaces/manual contact is continuous or intermittent light touch to assist balance or coordination
ambulation occurs on level surfaces without manual contact of another person/requires stand-by guarding of one person because of poor judgment, questionable cardiac status, or the need for verbal cuing to complete the task
ambulation is independent on level surfaces/requires supervision/physical assistance to negotiate stairs, inclines, or unlevel surfaces
ambulation is independent on unlevel and level surfaces, stairs and inclines</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Enrolled Subjects</title>
            <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity Measured by Functional Ambulation Category</title>
          <description>Activity measured by Functional Ambulation Category (FAC)
unable to ambulate/ambulates only in parallel bars/requires supervision or physical assistance from &gt; 1 person
requires manual contact of one person during ambulation on level surfaces/manual contact is continuous and necessary to support body weight and/or to maintain balance or assist coordination
requires manual contact of one person during ambulation on level surfaces/manual contact is continuous or intermittent light touch to assist balance or coordination
ambulation occurs on level surfaces without manual contact of another person/requires stand-by guarding of one person because of poor judgment, questionable cardiac status, or the need for verbal cuing to complete the task
ambulation is independent on level surfaces/requires supervision/physical assistance to negotiate stairs, inclines, or unlevel surfaces
ambulation is independent on unlevel and level surfaces, stairs and inclines</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average FAC Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average FAC Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gait Speed (Without Indego) Measured With 10 Meter Walk Test</title>
        <description>10 Meter Walk Test (MWT) without Indego to measure gait speed</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Enrolled Subjects</title>
            <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Speed (Without Indego) Measured With 10 Meter Walk Test</title>
          <description>10 Meter Walk Test (MWT) without Indego to measure gait speed</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average 10 MWT time Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average 10 MWT time Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Measured With Face, Legs, Activity, Cry, Consolability Scale</title>
        <description>Pain measured with Face, Legs, Activity, Cry, Consolability (FLACC) Scale Face 0: no particular expression or smile
occasional grimace or frown, withdrawn, disinterested
frequent to constant frown, clenched jaw, quivering chin
Legs 0: normal position or relaxed
uneasy, restless, tense
kicking, or legs drawn up
Activity 0: lying quietly, normal position, moves easily
squirming, shifting back and forth, tense
arched, rigid, or jerking
Cry 0: no cry (awake or asleep)
moans or whimpers, occasional complaint
crying steadily, screams or sobs, frequent complaints
Consolability 0: content, relaxed
reassured by occasional touching, hugging, or being talked to, distractable
difficult to console or comfort
Minimum score: 0 Maximum Score: 10</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Enrolled Subjects</title>
            <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Measured With Face, Legs, Activity, Cry, Consolability Scale</title>
          <description>Pain measured with Face, Legs, Activity, Cry, Consolability (FLACC) Scale Face 0: no particular expression or smile
occasional grimace or frown, withdrawn, disinterested
frequent to constant frown, clenched jaw, quivering chin
Legs 0: normal position or relaxed
uneasy, restless, tense
kicking, or legs drawn up
Activity 0: lying quietly, normal position, moves easily
squirming, shifting back and forth, tense
arched, rigid, or jerking
Cry 0: no cry (awake or asleep)
moans or whimpers, occasional complaint
crying steadily, screams or sobs, frequent complaints
Consolability 0: content, relaxed
reassured by occasional touching, hugging, or being talked to, distractable
difficult to console or comfort
Minimum score: 0 Maximum Score: 10</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average FLACC Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average FLACC Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Subjects</title>
          <description>All enrolled subjects will receive gait training with the Indego.
Indego Exoskeleton: Six study sessions including five Indego training sessions over two weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <description>Patient came to first Indego session and had BP 180/125. Patient admitted to hospital and they indicated that they forgot to take their BP medication that morning. Adverse Event determined to be unrelated to study/device. Subject withdrew from study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Patient was admitted to hospital for lower extremity deep vein thrombosis after being consented for study but before beginning first session. Adverse Event determined to be unrelated to study and device. Subject withdrew from study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <description>Patient was admitted to hospital for urinary retention that was resolved with foley catheter. Adverse Event determined to be unrelated to study and device.Subject withdrew from study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Patient noted posterior loss of balance falling after attempting to retrieve pillow off ground at home while gripping walker. Determined to be unrelated to study and device.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>Patient reported fall out of wheelchair. Determined to be unrelated to study and device.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Change in status</sub_title>
                <description>Patient had been consented for study but upon arriving for first session subject had poor verbal responsiveness with increased pushing behavior. Change in status determined to be unrelated to study and device. Subject withdrew from study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Loss of balance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abrasion</sub_title>
                <description>Subject had skin abrasion from personal AFO use on left lateral calf. Area did not come in contact with Indego and was present prior to use.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abrasion</sub_title>
                <description>Additional areas of breakdown and blisters from subject's personal AFO developed over the weekend (between Indego sessions).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan J. Farris, Ph.D., P.E.</name_or_title>
      <organization>Parker Hannifin Corporation</organization>
      <phone>2168963335</phone>
      <email>ryan.farris@parker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

